Ralstonia Effector Proteins for Programmable DNA Binding

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current technologies lack efficient mechanisms for creating targeted biological circuits and designer proteins that can specifically bind to predetermined DNA sequences, limiting their applications in genome engineering and therapeutic interventions.

Innovation Solution

Development of Ralstonia proteins with repeat variable diresidues (RVDs) that correspond directly to nucleotides, enabling precise protein-DNA recognition and facilitating targeted applications such as homologous recombination and therapeutic interventions against pathogens.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Adaptability or versatility

If TAL proteins are used for DNA binding, then programmable DNA binding is achieved, but the system lacks efficiency in creating targeted biological circuits

Engineering Contradiction:
Improveprogrammable DNA bindingVSAvoidefficiency in creating targeted biological circuits
Core Design Contradiction:
Adaptability or versatilityVSProductivity

Solution Approach 1:

The Ralstonia effector protein is divided into modular repeat units, each containing a RVD domain that independently recognizes a specific nucleotide. This segmentation allows for systematic assembly of proteins with customized DNA binding specificities by simply changing the RVD sequence, thereby improving efficiency in creating targeted biological circuits.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The Ralstonia effector proteins serve multiple functions: they can act as transcription factors, nucleases, or be fused with other functional domains. This multi-functionality allows a single protein platform to be used across various applications including genome engineering, gene regulation, and therapeutic interventions, enhancing productivity.

Inventive Principle:
Principle #6Universality (Multi-functionality)

2Reliability

If Xanthomonas TAL proteins are used, then DNA binding capability is obtained, but specificity and target site prediction accuracy are limited

Engineering Contradiction:
ImproveDNA binding capabilityVSAvoidtarget site prediction accuracy
Core Design Contradiction:
ReliabilityVSMeasurement precision

Solution Approach 1:

The RVD domain within each repeat unit is engineered to have localized and specific nucleotide recognition capability. Each RVD (comprised of two amino acids at positions 12 and 13 of the repeat) is designed to recognize a specific nucleotide base through local chemical interactions, enabling precise prediction of target sites based on the RVD sequence without context dependence.

Inventive Principle:
Principle #3Local quality

3Adaptability or versatility

If Ralstonia effectors are engineered with custom RVDs, then target site prediction becomes possible, but protein design complexity increases

Engineering Contradiction:
Improvetarget site prediction capabilityVSAvoidprotein design complexity
Core Design Contradiction:
Adaptability or versatilityVSDevice complexity

Solution Approach 1:

The systematic RVD-nucleotide correspondence rules serve as a copyable design template. Once the RVD recognition code is established, designing new target-specific effectors becomes a matter of copying and assembling known RVD units in the desired sequence, dramatically simplifying protein design while maintaining high target site prediction accuracy.

Inventive Principle:
Principle #26Copying

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The Ralstonia proteins provide high specificity and versatility for research and biotechnological applications, including genome engineering and therapeutic uses by enabling precise binding to target DNA sequences, enhancing traits in plants and bacteria, and providing therapeutic options against pathogens.

Implementation Method 1

the repeat variable diresidues (RVDs) of Ralstonia effectors correspond to the nucleotides in their target sites in a direct, linear fashion, one RVD to one nucleotide

Methodology Applied
Scientific EffectProtein-DNA recognition:

Data Source

PatentUS10844361B2Site-specific enzymes and methods of use
Publication Date: 2020.11.24 POSEIDA THERAPEUTICS INC
  • US10844361B2 patent drawing
  • US10844361B2 patent drawing

AI summary

The present invention provides polypeptides related to Ralstonia proteins, nucleic acids encoding the same, compositions comprising the same, kits comprising the same, non-human transgenic animals comprising the same, and methods of using the same.